All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2021 ASCO Annual Meeting, the GvHD Hub spoke with Delaney Wolfe, The Ohio State University, Columbus, US. We asked, What are the unique challenges to cytomegalovirus (CMV) prophylaxis in patients with acute or chronic GvHD?
What are the unique challenges to CMV prophylaxis in patients with acute or chronic GvHD?
Wolfe evaluates the use of letermovir for CMV prophylaxis. This includes the need for long-term data that observes treatment past day 100 post-allo-HCT, the challenges for CMV monitoring in patients who progress to chronic GvHD, and whether the benefits of letermovir outweigh its costs.
Subscribe to get the best content related to GvHD delivered to your inbox